EyeYon Medical

Executive Summary

EyeYon Medical, an Israeli biotech company founded in 2020, is advancing a proprietary sustained-release ocular drug delivery platform designed to address the significant unmet need in retinal diseases. Current standard-of-care requires frequent intravitreal injections, often monthly, imposing a heavy burden on patients and healthcare systems. EyeYon's biodegradable polymer implants enable controlled, long-term release of small-molecule and biologic therapeutics directly to the back of the eye, potentially extending dosing intervals to every six months or longer. This technology could dramatically improve patient compliance and outcomes while reducing treatment costs. The company has raised $30 million to date and operates with a team of 50–200 employees, focusing on preclinical development of its lead candidates. EyeYon is targeting several major retinal indications, including diabetic macular edema and wet age-related macular degeneration, which collectively represent multi-billion-dollar markets. While still in the preclinical stage, the platform's differentiation lies in its ability to deliver both small molecules and biologics with tunable release profiles. Success in upcoming studies could validate the platform and attract strategic partnerships with larger ophthalmology players. With strong intellectual property and an experienced management team, EyeYon Medical is positioned to become a key player in the evolving landscape of long-acting ocular therapies.

Upcoming Catalysts (preview)

• Q3 2026Release of preclinical proof-of-concept data for lead small-molecule candidate80% success
• Q4 2026Announcement of strategic partnership with a major ophthalmology company50% success
• Q4 2026Series B financing round to support IND-enabling studies70% success